RxDoctor Payments Data

Samuel Ani, MD

Hospitalist · Bay Shore, NYNPI 1417199605

Payments from drug & device makers

$2,647in general payments, 2019–2025

Across 97 payments — averaging $27.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$622
  • Shionogi Inc$377
  • Merck$348
  • Melinta Therapeutics, LLC$347
  • Gilead$252
  • Abbott$141
  • plus $559 from 14 others

What the payments were for

  • Food & beverage$2,647100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,647 in reported general payments places this provider in the 95th percentile of 1,860 hospitalist providers in New York.

See all hospitalist providers in New York

Medicare billing

Part B allowed, 2024
$171,810
Medicare patients
588
Services billed
1,808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol50$35,784
RybelsusSemaglutide18$20,984
JardianceEmpagliflozin13$15,225
JanumetSitagliptin Phos/Metformin Hcl11$10,812
JentaduetoLinagliptin/Metformin Hcl14$10,170
EliquisApixaban11$9,283
Atorvastatin Calcium192$1,955
Albuterol Sulfate HfaAlbuterol Sulfate40$1,407
Cefpodoxime Proxetil24$926
Losartan Potassium110$906
Levothyroxine Sodium34$798
Amlodipine Besylate150$784
Metoprolol Succinate54$752
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide43$696
Halobetasol Propionate11$693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Jentadueto$35$25,39627 claims
MerckJanumet$348$10,81211 claims
PfizerEliquis$131$9,28311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,860 hospitalist providers in New York.

Other hospitalist in Bay Shore

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →